CN102574845B - 1H-咪唑并[4,5-c]喹啉酮衍生物 - Google Patents

1H-咪唑并[4,5-c]喹啉酮衍生物 Download PDF

Info

Publication number
CN102574845B
CN102574845B CN201080034616.0A CN201080034616A CN102574845B CN 102574845 B CN102574845 B CN 102574845B CN 201080034616 A CN201080034616 A CN 201080034616A CN 102574845 B CN102574845 B CN 102574845B
Authority
CN
China
Prior art keywords
pyridyl
methyl
pyridin
substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080034616.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102574845A (zh
Inventor
P·菲雷
F·S·卡尔特霍夫
R·马
C·拉格特
F·施陶费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102574845(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102574845A publication Critical patent/CN102574845A/zh
Application granted granted Critical
Publication of CN102574845B publication Critical patent/CN102574845B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080034616.0A 2009-06-04 2010-06-02 1H-咪唑并[4,5-c]喹啉酮衍生物 Expired - Fee Related CN102574845B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18414109P 2009-06-04 2009-06-04
US61/184,141 2009-06-04
PCT/EP2010/057719 WO2010139731A1 (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

Publications (2)

Publication Number Publication Date
CN102574845A CN102574845A (zh) 2012-07-11
CN102574845B true CN102574845B (zh) 2015-09-02

Family

ID=42697442

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080034616.0A Expired - Fee Related CN102574845B (zh) 2009-06-04 2010-06-02 1H-咪唑并[4,5-c]喹啉酮衍生物

Country Status (30)

Country Link
US (2) US8476294B2 (enExample)
EP (1) EP2438064A1 (enExample)
JP (1) JP5596137B2 (enExample)
KR (1) KR101445458B1 (enExample)
CN (1) CN102574845B (enExample)
AR (1) AR076949A1 (enExample)
AU (1) AU2010255727B2 (enExample)
BR (1) BRPI1010621A2 (enExample)
CA (1) CA2763821A1 (enExample)
CL (1) CL2011003052A1 (enExample)
CO (1) CO6470887A2 (enExample)
CR (1) CR20110608A (enExample)
CU (1) CU24064B1 (enExample)
DO (1) DOP2011000373A (enExample)
EA (1) EA020715B1 (enExample)
EC (1) ECSP11011500A (enExample)
GE (1) GEP20156267B (enExample)
IL (1) IL216452A0 (enExample)
MA (1) MA33332B1 (enExample)
MX (1) MX2011012943A (enExample)
NI (1) NI201100209A (enExample)
NZ (1) NZ596487A (enExample)
PE (1) PE20120224A1 (enExample)
SG (1) SG176572A1 (enExample)
TN (1) TN2011000626A1 (enExample)
TW (1) TWI464168B (enExample)
UA (1) UA106074C2 (enExample)
UY (1) UY32682A (enExample)
WO (1) WO2010139731A1 (enExample)
ZA (1) ZA201108439B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
KR20140014104A (ko) * 2010-12-06 2014-02-05 피라말 엔터프라이지즈 리미티드 치환된 이미다조퀴놀린 유도체
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9284315B2 (en) 2011-11-17 2016-03-15 Zuanzhu Pharma Co., Ltd. Three-ring PI3K and/or mTOR inhibitor
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
JP6419783B2 (ja) 2013-04-15 2018-11-07 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 殺菌・殺カビ性アミド
CN105531348B (zh) * 2013-09-11 2017-11-07 默克专利有限公司 杂环化合物
CN104513254B (zh) 2013-09-30 2019-07-26 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
JP6606428B2 (ja) * 2013-10-11 2019-11-13 国立大学法人 東京医科歯科大学 脊髄小脳変性症を予防又は治療するための薬剤
CN104447740B (zh) * 2013-11-20 2017-02-22 北京富龙康泰生物技术有限公司 咪唑酮类衍生物、其药物组合物和用途
NO2714752T3 (enExample) 2014-05-08 2018-04-21
HRP20181670T1 (hr) 2014-06-03 2018-12-14 Idorsia Pharmaceuticals Ltd Spojevi pirazola i njihova uporaba kao blokatora kalcijevih kanala t-tipa
HUE054745T2 (hu) * 2015-04-02 2021-09-28 Merck Patent Gmbh Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10988472B2 (en) 2016-10-13 2021-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for blocking transmission of malarial parasite
EP3554490B1 (en) 2016-12-16 2022-02-16 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
TWI808960B (zh) 2017-02-06 2023-07-21 瑞士商愛杜西亞製藥有限公司 用於合成1-芳基-1-三氟甲基環丙烷之新穎方法
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CA3154475A1 (en) * 2019-09-23 2021-04-01 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
US20230380203A1 (en) * 2021-01-26 2023-11-23 Boe Technology Group Co., Ltd. Quantum dot light-emitting device, display apparatus and manufacturing method
CN116768928A (zh) * 2023-06-15 2023-09-19 上海毕臣生化科技有限公司 一种3-叔丁基-5-硼酸酯基吡啶的合成方法
CN117384154A (zh) * 2023-09-04 2024-01-12 广州医科大学 一种吡咯并喹啉酮化合物、合成方法及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097641A2 (en) * 2002-05-21 2003-11-27 Novartis Ag 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
WO2005054238A1 (en) * 2003-11-21 2005-06-16 Novartis Ag 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
WO2006122806A2 (en) * 2005-05-20 2006-11-23 Novartis Ag 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors
WO2008103636A1 (en) * 2007-02-20 2008-08-28 Novartis Ag Imidazoquinolines as dual lipid kinase and mtor inhibitors
WO2009013305A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416801A (pt) 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
AU2005284835A1 (en) 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
CN101309687A (zh) 2005-11-04 2008-11-19 科勒制药集团公司 经羟基和烷氧基取代的1h-咪唑并喹啉及其方法
MX2009005360A (es) 2006-11-20 2009-06-05 Novartis Ag Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinol in-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propion itrilo.
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
CA2717948C (en) 2008-03-26 2016-09-06 Novartis Ag 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
US20110212053A1 (en) 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097641A2 (en) * 2002-05-21 2003-11-27 Novartis Ag 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases
WO2005054238A1 (en) * 2003-11-21 2005-06-16 Novartis Ag 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
WO2006122806A2 (en) * 2005-05-20 2006-11-23 Novartis Ag 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors
WO2008103636A1 (en) * 2007-02-20 2008-08-28 Novartis Ag Imidazoquinolines as dual lipid kinase and mtor inhibitors
WO2009013305A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions

Also Published As

Publication number Publication date
US20100317657A1 (en) 2010-12-16
TN2011000626A1 (en) 2013-05-24
CU24064B1 (es) 2014-12-26
UA106074C2 (uk) 2014-07-25
EA201101704A1 (ru) 2012-07-30
NI201100209A (es) 2012-02-02
TW201102386A (en) 2011-01-16
BRPI1010621A2 (pt) 2016-06-21
JP5596137B2 (ja) 2014-09-24
WO2010139731A1 (en) 2010-12-09
EA020715B1 (ru) 2015-01-30
UY32682A (es) 2011-01-31
US8476294B2 (en) 2013-07-02
AR076949A1 (es) 2011-07-20
SG176572A1 (en) 2012-01-30
US20140005163A1 (en) 2014-01-02
IL216452A0 (en) 2012-01-31
JP2012528828A (ja) 2012-11-15
DOP2011000373A (es) 2011-12-31
CO6470887A2 (es) 2012-06-29
ZA201108439B (en) 2012-08-29
TWI464168B (zh) 2014-12-11
CL2011003052A1 (es) 2012-08-31
MA33332B1 (fr) 2012-06-01
GEP20156267B (en) 2015-04-14
CA2763821A1 (en) 2010-12-09
AU2010255727A1 (en) 2011-12-08
CR20110608A (es) 2012-01-16
EP2438064A1 (en) 2012-04-11
KR101445458B1 (ko) 2014-10-07
CU20110221A7 (es) 2012-03-15
PE20120224A1 (es) 2012-04-04
KR20120034710A (ko) 2012-04-12
AU2010255727B2 (en) 2013-02-28
CN102574845A (zh) 2012-07-11
MX2011012943A (es) 2012-01-27
NZ596487A (en) 2012-11-30
ECSP11011500A (es) 2012-01-31

Similar Documents

Publication Publication Date Title
CN102574845B (zh) 1H-咪唑并[4,5-c]喹啉酮衍生物
US20100311714A1 (en) 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
JP5436507B2 (ja) アザインドール
US8188113B2 (en) Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CA2451678C (en) Azaindoles
CA2981365A1 (en) Imidazolonylquinolines and the use thereof as atm kinase inhibitors
AU2013249041A1 (en) Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an HIV infection
CN111868037B (zh) 作为crhr2拮抗剂的稠合环状脲衍生物
CN105051047A (zh) 化学个体
US20240109900A1 (en) Azabicyclic shp2 inhibitors
JP6847954B2 (ja) キナーゼ阻害剤としての三環式化合物および組成物
CN118434744A (zh) 含氮大环类化合物及其制备方法和医药用途
JP4871474B2 (ja) アザインドール
CN103596953A (zh) 吡啶并萘啶类P13K和mTOR双重抑制剂及其制备与应用
US20250114345A1 (en) Compounds and compositions as cbp/p300 degraders and uses thereof
HK40037565A (en) Fused cyclic urea derivatives as crhr2 antagonist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150902

Termination date: 20170602